<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04175041</url>
  </required_header>
  <id_info>
    <org_study_id>2018P002889</org_study_id>
    <nct_id>NCT04175041</nct_id>
  </id_info>
  <brief_title>A Dose-Response Study of the Cognitive and Physiological Effects of tDCS to the DLPFC</brief_title>
  <official_title>A Dose-Response Study of the Cognitive and Physiological Effects of tDCS to the DLPFC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the cognitive and neurophysiological dose-response relationships of anodal tDCS
      to the left DLPFC as a function of absolute current intensity, individualized E-field
      intensity, and stimulation duration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the cognitive and neurophysiological dose-response relationships of anodal tDCS
      to the left DLPFC as a function of absolute current intensity, individualized E-field
      intensity, and stimulation duration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Accuracy and Reaction Time in Attention and Working Memory</measure>
    <time_frame>Change Before and After Stimulation on Each of the Four Visits, Average of 2-6 Weeks</time_frame>
    <description>Measured using Eriksen Flanker Task (EFT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amplitude of Electroencephalogram (EEG) Event Related Potentials</measure>
    <time_frame>Change Before and After Stimulation on Each of the Four Visits, Average of 2-6 Weeks</time_frame>
    <description>Measure of amplitude related to stimulus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>ADHD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with ADHD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Volunteers without Neuropsychiatric Disorders.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Direct Current Stimulation</intervention_name>
    <description>In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.</description>
    <arm_group_label>ADHD</arm_group_label>
    <arm_group_label>Healthy Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Patients)

          1. Male and female outpatients 18-55 years of age

          2. A diagnosis of ADD/ADHD or meeting the Diagnostic and Statistical Manual of Mental
             Disorders, Fifth Edition (DSM-5) criteria.

          3. Patient will be either off stimulant medications or, if undergoing treatment with
             stimulants, will be asked to discontinue two days prior to the experiment, under
             physician-guided protocol, and allowed to resume afterwards. Subjects may resume
             stimulant use between the two study visits so long as they discontinue use two days
             prior to the second study visit. If fatigue is problematic in subjects discontinuing
             medication, they will be allowed to continue with the study if they are able to follow
             the suggested taper plan (50% of the dose day one, 25% dose day 2, stop day of visit
             (day 3)).

          4. If on non-stimulant medications, dose must have been stable for at least 4 weeks.

        Exclusion Criteria (Patients)

          1. Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck,
             brain stimulators, vagus nerve stimulators, VP shunt, pacemakers, pregnancy.

          2. Active substance dependence (except for tobacco).

          3. Pregnant or nursing females.

          4. Inability to participate in testing procedures.

        Inclusion Criteria (Healthy Control)

        1. Male and female outpatients 18-55 years of age

        Exclusion Criteria (Healthy Control)

          1. Diagnosis of psychiatric of neurological disorder

          2. Ongoing treatment with any psychotropic medications.

          3. Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck,
             brain stimulators, vagus nerve stimulators, VP shunt, pacemakers, pregnancy.

          4. Active substance dependence (except for tobacco).

          5. Pregnant or nursing females.

          6. Inability to participate in testing procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Camprodon, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joan Camprodon, MD, PhD, MPH</last_name>
    <phone>61772656348</phone>
    <email>jcamprodon@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Cirillo, MD, PhD</last_name>
    <phone>6177243217</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Funes, MS</last_name>
      <phone>617-724-8780</phone>
      <email>cjfunes@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Joan A Camprodon, MD MPH PhD</investigator_full_name>
    <investigator_title>Chief of Division of Neuropsychiatry, Director of TMS Clinic, Director of Lab for Neuropsychiatry and Neuromodulation</investigator_title>
  </responsible_party>
  <keyword>Transcranial Direct Current Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

